More DCAT Value Chain Insights

In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.

How did the pharmaceutical industry perform in 2017, and what is the outlook for 2018 and beyond? Key for the industry is the performance of the US market, the largest national market in the global pharmaceutical industry, but what other factors...

An effective supply strategy is crucial for pharmaceutical companies, so what are the challenges that companies face? Managing risk, addressing shifts in product mix, and increasingly complex supply chains are some of the challenges. The DCAT Week...

Biopharmaceutical companies invest approximately $75 billion annually in R&D in the US, more than any other industry in the US. There are more than 7,000 drugs in development, with more than three-quarters defined as first-in-class, meaning...

A recent study by PwC examines the thinking and strategic direction of CEOs and how their views compare with the perceptions and expectations of investment professionals. So what did the study show? Investment professionals and CEOs both think...

Vasant Narasimhan, MD, took the helm of Novartis on February 1, 2018, assuming the role of CEO following the retirement of former CEO Joseph Jimenez. So what does the new CEO face? Key for Narasimhan will be to drive growth in the company's...

In its annual assessment of technology advances, Accenture highlights that rapid advancements in technologies, including artificial intelligence, advanced analytics and the cloud, are enabling companies to not just create innovative products and...

What do parenteral drugs and healthcare reform have in common? Recent reports point to the relationship between the high cost of specialty drugs, often parenteral drugs administered in hospitals. So what did the reports show and what are the...